TrivarX (ASX:TRI) Short-Term Debt : A$0.06 Mil (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is TrivarX Short-Term Debt?

TrivarX's Short-Term Debt for the quarter that ended in Dec. 2023 was A$0.06 Mil.

TrivarX's quarterly Short-Term Debt declined from Dec. 2022 (A$0.02 Mil) to Jun. 2023 (A$0.00 Mil) but then increased from Jun. 2023 (A$0.00 Mil) to Dec. 2023 (A$0.06 Mil).

TrivarX Short-Term Debt Historical Data

The historical data trend for TrivarX's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TrivarX Short-Term Debt Chart

TrivarX Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Short-Term Debt

Get a 7-Day Free Trial

2.75

TrivarX Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Short-Term Debt	Get a 7-Day Free Trial															0.08	-	0.02	-	0.06

TrivarX Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

TrivarX Short-Term Debt Related Terms

Thank you for viewing the detailed overview of TrivarX's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

TrivarX (ASX:TRI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » TrivarX Ltd (ASX:TRI) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

MDBIF:USA

Address

647 Beaufort Street, Mount Lawley, WA, AUS, 6050

Website

https://www.medibio.com.au

TrivarX Ltd Formerly Medibio Ltd is a medical technology company. The principal activity of the company is conducting clinical research, product development, and early-stage commercialization of mental health technology using objective biomarkers to assist in the screening, diagnosing monitoring, and management of depression and other mental health conditions. It serves both consumer and healthcare provider markets. In addition, the company offers various psychological services to customers in Australia. The company operates in two geographical markets; Australia and the United States. The company has one operating segment, being the research, development, and commercialization of its Software as a Service product.